Search Results - "Ezekekwu, Chinedu A."

Plasma concentration of fucosyltransferase 7 is not associated with the number of clinically overt vaso-occlusive events in sickle cell disease by Okpala, Iheanyi E, Eze, Onyinye E, Ezekekwu, Chinedu A, Nnakenyi, Ifeyinwa D, Ilechukwu, Gladys U, Akpa, Chinedu O, Nwani, Emmanuel I, Maduka, Collins J, Anigbogu, Ikechukwu O, Muoghalu, Ebele D, Ugwu, Ngozi I, Ajuba, Ifeoma C, Aneke, John C, Okoye, Helen C, Nonyelu, Charles C, Duru, Augustine N

“…Objective: To determine if the number of vaso-occlusive events in SCD relates to plasma concentration of fucosyl-transferase 7 (FUT7), which catalyses the…”
Get full text

Associations of α-thalassemia and BCL11A with stroke in Nigerian, United States, and United Kingdom sickle cell anemia cohorts by Saraf, Santosh L., Akingbola, Titilola S., Shah, Binal N., Ezekekwu, Chinedu A., Sonubi, Omowunmi, Zhang, Xu, Hsu, Lewis L., Gladwin, Mark T., Machado, Roberto F., Cooper, Richard S., Gordeuk, Victor R., Tayo, Bamidele O.

“…α-Thalassemia and the BCL11A rs1427407 T allele are commonly observed in sickle cell anemia (SCA) patients and are associated with reduced hemolysis and higher…”
Get full text

“Maximum tolerated dose” vs “fixed low‐dose” hydroxyurea for treatment of adults with sickle cell anemia by Akingbola, Titilola S., Tayo, Bamidele O., Ezekekwu, Chinedu A., Sonubi, Omowunmi, Zhang, Xu, Saraf, Santosh L., Molokie, Robert, Hsu, Lewis L., Han, Jin, Cooper, Richard S., Gordeuk, Victor R.

Get full text

Fixed low‐dose hydroxyurea for the treatment of adults with sickle cell anemia in Nigeria by Tayo, Bamidele O., Akingbola, Titilola S., Saraf, Santosh L., Shah, Binal N., Ezekekwu, Chinedu A., Sonubi, Omowunmi, Hsu, Lewis L., Cooper, Richard S., Gordeuk, Victor R.

Get full text

Molecular and Clinicopathological Correlates of Wild-Type KRAS Expression in Prostate Cancer by Ebili, Henry O., Omenai, Sebastian A., Ezenkwa, Uchenna S., Ale, Ayotunde O., Akintola, Patrick A., Adetona, Adesoji E., Akunwata, Chima U., Mashor, Mbwas I., Nwanji, Ifeanyichukwu D., Iyapo, Oluwadamilare, Ezekekwu, Chinedu A., Akulue, John C., Chidozie, Ngozi

“…Background The clinicopathological significance of KRAS alterations in clinical prostate cancer (PCa) has yet to be comprehensively studied, and the classic…”
Get full text

The Interaction of Sickle Cell Trait and Anticardiolipin Antibodies in Venousthromboembolism by Ezekekwu, Chinedu A, Kotila, Taiwo R, Anyanwu-Yeiya, Chinonso Chiemeka, Akingbola, Titilola S., Tayo, Bamidele

“…Introduction Among the risk factors for venous thromboembolism (VTE) are inheritance of the sickle cell gene and antiphospholipid syndrome. Antiphospholipid…”
Get full text

Maximum Tolerated Dose Versus Fixed Low-Dose Hydroxyurea for Treatment of Adults with Sickle Cell Anemia - Retrospective Comparison of Two Studies by Akingbola, Titilola S., Tayo, Bamidele, Ezekekwu, Chinedu A, Sonubi, Omowunmi, Saraf, Santosh L., Hsu, Lewis L., Han, Jin, Cooper, Richard S., Gordeuk, Victor R.

“…Background. Despite a large body of evidence that hydroxyurea is effective for sickle cell anemia (SCA), utilization with the “maximum tolerated dose” regimen…”
Get full text

Low Fixed Dose Hydroxyurea for the Treatment of Adults with Sickle Cell Disease in Nigeria by Akingbola, Titilola S., Tayo, Bamidele, Saraf, Santosh L., Shah, Binal N., Ezekekwu, Chinedu A, Sonubi, Omowunmi, Hsu, Lewis L., Cooper, Richard S., Gordeuk, Victor R.

“…▪ Background: The vast majority of births with sickle cell anemia occur in Africa 1 and early-life mortality, generally before age five years, is as high as…”
Get full text

Fixed low‐dose hydroxyurea for the treatment of adults with sickle cell anemia in N igeria by Tayo, Bamidele O., Akingbola, Titilola S., Saraf, Santosh L., Shah, Binal N., Ezekekwu, Chinedu A., Sonubi, Omowunmi, Hsu, Lewis L., Cooper, Richard S., Gordeuk, Victor R.

Get full text

“Maximum Tolerated Dose” versus “Fixed Low-Dose” Hydroxyurea for Treatment of Adults with Sickle Cell Anemia by Akingbola, Titilola S., Tayo, Bamidele O., Ezekekwu, Chinedu A., Sonubi, Omowunmi, Zhang, Xu, Saraf, Santosh L., Molokie, Robert, Hsu, Lewis L., Han, Jin, Cooper, Richard S., Gordeuk, Victor R.

Get full text

Plasma concentration of fucosyltransferase 7 is not associated with the number of clinically overt vaso-occlusive events in sickle cell disease by Okpala, Iheanyi E, Eze, Onyinye E, Ezekekwu, Chinedu A, Nnakenyi, Ifeyinwa D, Ilechukwu, Gladys U, Akpa, Chinedu O, Nwani, Emmanuel I, Maduka, Collins J, Anigbogu, Ikechukwu O, Muoghalu, Ebele D, Ugwu, Ngozi I, Ajuba, Ifeoma C, Aneke, John C, Okoye, Helen C, Nonyelu, Charles C, Duru, Augustine N

“…To determine if the number of vaso-occlusive events in SCD relates to plasma concentration of fucosyltransferase 7 (FUT7), which catalyses the synthesis of…”
Get more information